Stada Group
Gerald Pedrassi has extensive work experience in pharmaceutical development and management roles. Gerald is currently the VP of Global Pharmaceutical Development at STADA Group. Prior to this, they worked at Galderma as the Director and Head of CMC Development, where they were responsible for overseeing the design and development of Chemistry, Manufacturing, and Control programs for prescription products. Gerald also worked at Nestlé Skin Health in various roles, including Product Innovation Director, Head of Global Prescription Pharmaceutical Development, and Acting Head of Global Self-Medication Product Development. Additionally, they have experience at Arkopharma as a Liquids and Semi-Solids Production Manager, and at Servier as a Production Unit Director and Quality Assurance Pharmacist.
Gerald PEDRASSI received a Doctor in Pharmacy degree from the Faculté de Pharmacie de Montpellier in 1995. Gerald also obtained a Diplôme d'ingénieur in Organic Chemistry from the Ecole Nationale Supérieure de Chimie de Montpellier from 1994 to 1996. Additionally, they pursued DEA Pharmacologie & Chimie Thérapeutique at the Faculté de Pharmacie de Montpellier from 1989 to 1995. Gerald completed their secondary education at Lycée Jean Moulin, but no specific degree information is provided.
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.